Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning of serious or life-threatening behavioral and psychiatric reactions in patients taking Fycompa™.
Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -
Perampanel
Drug Overview
What is Perampanel?
To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).
Request Your Assessment
Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.
View Inquiry List →Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
Regulatory Framework
Assessment Methodology
Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.
EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)
Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.
PIC/S – Shared Facilities and Contamination Control Guidance
Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.
ICH Q9 – Quality Risk Management
Provides a structured methodology for risk identification, assessment, control, communication, and review.
ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)
Applied for compounds with potential mutagenic or genotoxic concerns.
Risk-Based Toxicological Assessment
Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.
Weight-of-Evidence (WoE) Approach
Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.
How We Work
Report Preparation Process
Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.
Comprehensive Data Review
Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.
Scientific Evaluation
Identification of critical endpoints and selection of appropriate exposure limits.
PDE / HBEL Derivation
Transparent and scientifically justified calculations aligned with global toxicological principles.
Ex-Agency Expert Review (Our Differentiator)
Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.
Final Report Delivery
Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).
Ex-Agency Advantage
Why Masuu Global?
Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.
Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.
Inspection-ready reports — scientifically defensible and audit-prepared from day one.
Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).
Practical implementation recommendations that translate science into actionable contamination control.
Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.
Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.
Ready to request your assessment?
Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.
Frequently Asked Questions
Perampanel is an antiepileptic pharmaceutical substance. Its pharmacological activity and the available toxicological evidence may be relevant when assessing occupational exposure and potential carryover in pharmaceutical manufacturing. The available evidence and the intended handling conditions should guide any conclusions about exposure control, rather than relying on the name or chemical class alone.
A PDE or ADE sets a health-based limit on daily exposure to Perampanel from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.
Where relevant information is available, the pharmacological activity of Perampanel can help identify effects that may be important for a health-based exposure assessment. Evaluators consider the reliability and relevance of the evidence rather than assuming that therapeutic activity alone determines an exposure limit. The selected critical effect, dose-response basis, and uncertainty factors should be explained in the assessment.
If Perampanel is a substance with relevant therapeutic-use information, dose information may contribute context to the assessment, but it does not by itself establish a PDE, ADE, or OEL. The evaluator must consider the quality and relevance of the full evidence package, including critical effects and route of exposure. Any use of dose information should be scientifically justified and clearly documented.
A scientifically justified PDE for Perampanel can be used as a health-based input when evaluating potential residue carryover from shared equipment into a subsequent product. Cleaning validation also requires consideration of the process, equipment, analytical method, and applicable acceptance criteria. The PDE does not by itself establish every cleaning limit; its use and any additional calculations should be documented.
An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.
An OEB places Perampanel in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.
A Masuu Global assessment report for Perampanel presents the scientific rationale, relevant calculations, and clear recommendations supporting the assessment. Reports are prepared by certified toxicologists and are designed to be regulatory-ready. The scope and conclusions depend on the substance-specific evidence available and the assessment requested, so the report should clearly identify its assumptions, limitations, and intended application.
For Perampanel, the assessment can consider the tasks and conditions that may influence exposure, including material charging, transfer, sampling, equipment maintenance, and cleaning. The form handled, potential for dust or aerosol generation, process containment, and duration of work can affect the risk-management approach. Task-specific information helps connect the toxicological assessment with practical workplace controls.
The physical form in which Perampanel is handled, such as a powder, granulated material, or solution, can influence how exposure may occur during routine operations. The assessment should consider the actual process, opportunities for dust, droplets, or aerosols, and the effectiveness of containment and work practices. Physical form does not independently determine toxicity, but it can affect exposure control decisions.
Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.
Use the Request Your Assessment option on this page and add Perampanel to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.
